MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)

Status: Recruiting

Phase of Trial: Phase III/IV

Latest Information Update: 30 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary)
Indications Hypertrophic cardiomyopathy
Focus Therapeutic Use
Acronyms MEMENTO
Sponsors Bristol-Myers Squibb

Most Recent Events

20 Sep 2024 Planned End Date changed from 31 Dec 2026 to 31 Jul 2026.
20 Sep 2024 Planned primary completion date changed from 31 Jul 2025 to 31 Jul 2026.
20 Sep 2024 Status changed from to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight